4/A
Changes in Ownership
Amylyx Pharmaceuticals, Inc. Filed Acc 0000899243-23-009600
Chief Medical Officer sold 54,627 shares at an average $31.87 ($1,741,200)
- Chief Medical Officer acquired 49,578 shares (option exercise)
- Chief Medical Officer acquired 9,167 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Yeramian Patrick D Chief Medical Officer | 2023-03-16 | Option exercise | +2,789 | $0.33 | $920 | 207,088 | D |
| Yeramian Patrick D Chief Medical Officer | 2023-03-16 | Option exercise | +30,041 | $0.37 | $11,115 | 237,129 | D |
| Yeramian Patrick D Chief Medical Officer | 2023-03-16 | Option exercise | +16,748 | $6.88 | $115,226 | 253,877 | D |
| Yeramian Patrick D Chief Medical Officer | 2023-03-16 | Sale | −52,211 | $31.85 | $1,662,842 | 201,666 | D |
| Yeramian Patrick D Chief Medical Officer | 2023-03-16 | Sale | −2,416 | $32.43 | $78,358 | 199,250 | D |
| Yeramian Patrick D Chief Medical Officer | 2023-03-16 | Grant or award | +9,167 | 208,417 | D | ||
| Derivatives | |||||||
| Yeramian Patrick D Chief Medical Officer | 2023-03-16 | Grant or award · Stock Option (right to buy) | +41,250 | 41,250 | D | ||
| Yeramian Patrick D Chief Medical Officer | 2023-03-16 | Option exercise · Stock Option (right to buy) | −2,789 | 0 | D | ||
| Yeramian Patrick D Chief Medical Officer | 2023-03-16 | Option exercise · Stock Option (right to buy) | −30,041 | 62,466 | D | ||
| Yeramian Patrick D Chief Medical Officer | 2023-03-16 | Option exercise · Stock Option (right to buy) | −16,748 | 48,252 | D | ||
| Open-market sales · 54,627 sh · avg $31.87 · $1,741,200 | |||||||
Loading xslF345X04/doc4a.xml…